Samsung Biologics Capacity Update May 2024: Large Molecule Development

The therapeutic promise of biologicals has fundamentally changed health care. Samsung Biologics is committed to helping drug developers bring these promising new therapeutics to patients.

To accelerate the availability of biological therapeutics to drug developers, Samsung Biologics provides programs for the entire life cycle of mammalian derived biologicals and bioconjugates, from preclinical to commercial stages, from drug substance to drug product.

Bioconjugates pose a complex challenge from a development and manufacturing perspective. Samsung Biologics offers process development and manufacturing of the ADCs. These services are supported by a full suite of analytical methods to support characterization and release testing.